Loading…
Mankind Pharma (MANKIND)₹2,668+3.31%Pharmaceuticals
In the Sep 2026 quarter (consolidated), Mankind Pharma reported sales of ₹4,334 Cr, up 17.4% from Sep 2025, and net profit of ₹718 Cr, up 37.7% year on year. For the year to Mar 2026, sales were ₹14,271 Cr and net profit ₹1,942 Cr.
Company filings, consolidated accounts; latest reported quarter Sep 2026
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,605 | 2,423 | 2,866 | 3,060 | 3,199 | 3,078 | 3,570 | 3,693 | 3,564 | 3,441 | 4,029 | 4,334 |
| Expenses | 2,006 | 1,840 | 2,201 | 2,218 | 2,388 | 2,403 | 2,730 | 2,783 | 2,655 | 2,518 | 2,983 | 3,174 |
| Operating Profit | 607 | 587 | 673 | 849 | 818 | 684 | 849 | 922 | 920 | 931 | 1,058 | 1,173 |
| OPM % | 23.1% | 24.1% | 23.0% | 28.1% | 26.0% | 22.0% | 24.1% | 25.1% | 26.0% | 27.0% | 26.0% | 27.0% |
| Other Income | 75.07 | 94.08 | 108 | 109 | 87.14 | 249 | 83.17 | 94.14 | −31.04 | 94.19 | 49.07 | 99.10 |
| Interest | 9.03 | 9.02 | 11.03 | 7.02 | 221 | 192 | 172 | 170 | 157 | 142 | 110 | 105 |
| Depreciation | 110 | 100 | 103 | 100 | 187 | 231 | 219 | 222 | 223 | 223 | 226 | 236 |
| Profit before tax | 563 | 573 | 668 | 851 | 496 | 512 | 541 | 625 | 510 | 661 | 771 | 930 |
| Tax % | 18.1% | 17.1% | 18.0% | 22.1% | 22.0% | 17.1% | 18.1% | 17.0% | 19.1% | 15.1% | 25.1% | 23.1% |
| Exceptional items | 0.00 | 0.00 | 5.01 | −1.99 | 7.01 | −3.99 | 0.00 | 0.00 | −73.97 | −16.01 | 0.00 | 0.00 |
| Net Profit | 461 | 478 | 545 | 661 | 386 | 426 | 446 | 521 | 415 | 560 | 575 | 718 |
| EPS (Rs) | 11.34 | 11.77 | 13.41 | 16.33 | 9.24 | 10.21 | 10.63 | 12.42 | 9.92 | 13.45 | 13.77 | 17.26 |
| Mar 2015 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,331 | 5,861 | 6,209 | 7,783 | 8,747 | 10,262 | 12,204 | 14,271 | 15,369 |
| Expenses | 2,757 | 4,437 | 4,576 | 5,803 | 6,868 | 7,759 | 9,211 | 10,674 | 11,330 |
| Operating Profit | 587 | 1,441 | 1,652 | 1,995 | 1,904 | 2,522 | 3,032 | 3,628 | 4,081 |
| OPM % | 18.1% | 25.0% | 27.0% | 26.1% | 22.0% | 25.1% | 25.0% | 25.0% | 26.6% |
| Other Income | 76.13 | 122 | 183 | 210 | 141 | 295 | 549 | 238 | 211 |
| Interest | 2.01 | 23.07 | 21.05 | 60.16 | 46.16 | 34.09 | 433 | 646 | 515 |
| Depreciation | 39.01 | 98.93 | 119 | 167 | 326 | 378 | 621 | 886 | 908 |
| Profit before tax | 623 | 1,442 | 1,696 | 1,980 | 1,675 | 2,405 | 2,527 | 2,339 | 2,872 |
| Tax % | 29.1% | 27.1% | 24.1% | 26.1% | 22.1% | 19.1% | 20.1% | 17.1% | — |
| Exceptional items | 0.00 | 33.02 | 48.02 | 63.97 | 28.99 | 106 | 195 | −102 | −89.98 |
| Net Profit | 446 | 1,058 | 1,297 | 1,457 | 1,314 | 1,948 | 2,016 | 1,942 | 2,268 |
| EPS (Rs) | 10.98 | 25.78 | 31.63 | 35.87 | 32.08 | 47.80 | 48.31 | 46.41 | 54.40 |
| Dividend payout % | 0.0% | 0.0% | 24.0% | 0.0% | 0.0% | 0.0% | 0.0% | 2.0% | — |
| Mar 2015 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 20.07 | 40.14 | 40.14 | 40.14 | 40.16 | 40.14 | 41.15 | 41.13 |
| Reserves | 2,035 | 3,448 | 4,687 | 6,119 | 7,407 | 9,339 | 14,301 | 16,277 |
| Borrowings | 0.00 | 131 | 242 | 876 | 171 | 208 | 8,538 | 6,337 |
| Other Liabilities | 973 | 1,456 | 1,404 | 2,090 | 2,090 | 2,324 | 4,831 | 5,168 |
| Total Liabilities | 3,027 | 5,075 | 6,372 | 9,126 | 9,708 | 11,912 | 27,712 | 27,823 |
| Fixed Assets | 317 | 1,606 | 1,669 | 3,601 | 4,268 | 4,563 | 19,056 | 18,678 |
| CWIP | 47.06 | 317 | 372 | 702 | 551 | 283 | 828 | 1,130 |
| Investments | 962 | 831 | 1,517 | 1,113 | 1,351 | 2,576 | 2,048 | 1,990 |
| Other Assets | 1,701 | 2,322 | 2,813 | 3,709 | 3,538 | 4,490 | 5,782 | 6,026 |
| Inventories | 645 | 900 | 1,186 | 1,764 | 1,501 | 1,554 | 2,098 | 2,148 |
| Trade receivables | 198 | 532 | 332 | 389 | 577 | 850 | 1,540 | 1,734 |
| Cash & equivalents | 39.15 | 421 | 704 | 407 | 455 | 710 | 556 | 485 |
| Total Assets | 3,027 | 5,075 | 6,372 | 9,126 | 9,708 | 11,912 | 27,712 | 27,823 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from operating activity | 1,068 | 1,136 | 919 | 1,812 | 2,151 | 2,411 | 3,118 |
| Cash from investing activity | −437 | −1,224 | −1,372 | −1,055 | −2,086 | −12,645 | −181 |
| Cash from financing activity | −532 | −8.02 | 606 | −742 | 5.01 | 10,254 | −2,960 |
| Net cash flow | 103 | −92.35 | 157 | 22.08 | 77.28 | 22.08 | −12.04 |
| Capex | 228 | 312 | 2,351 | 833 | 390 | 532 | 738 |
| Free cash flow | 853 | 826 | −1,424 | 988 | 1,771 | 1,895 | 2,388 |
| CFO / OP % | 97.0% | 96.0% | 71.0% | 112.0% | 103.0% | 98.0% | 102.0% |
| Mar 2015 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor days | 22 | 33 | 19 | 18 | 24 | 30 | 46 | 44 |
| Inventory days | 166 | 175 | 243 | 265 | 188 | 180 | 219 | 193 |
| Days payable | 71 | 145 | 137 | 162 | 126 | 90 | 119 | 121 |
| Cash conversion cycle | 116 | 62 | 124 | 120 | 85 | 119 | 145 | 116 |
| Working capital days | 56 | 30 | 32 | 24 | 39 | 53 | −28 | −40 |
| ROCE % | — | — | 37.0% | 32.0% | 22.0% | 26.0% | 17.0% | 14.0% |
For the Sep 2026 quarter, Mankind Pharma reported sales of ₹4,334 Cr, up 17.4% year on year and net profit of ₹718 Cr, up 37.7% year on year. The operating margin was 27.0%.
Mankind Pharma's sales for the year to Mar 2026 were ₹14,271 Cr; over the last twelve months they were ₹15,369 Cr.
Net profit for the year to Mar 2026 was ₹1,942 Cr, and ₹2,268 Cr over the last twelve months. Earnings per share over the same trailing period were ₹54.40.
Mankind Pharma reported borrowings of ₹6,337 Cr at Mar 2026, against cash and equivalents of ₹485 Cr.
Cash from operations was ₹3,118 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹2,388 Cr.